Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

被引：0
|
作者：
Moskowitz, Craig H.
Chen, Robert W.
Armand, Philippe
Zinzani, Pier Luigi
Vassilakopoulos, Theodoros P.
Goldmacher, Gregory V.
Lin, Jianxin
Nahar, Akash
Balakumaran, Arun
Salles, Gilles
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4085
引用
收藏
页数：4
相关论文
共 36 条
  • [1] Pembrolizumab in Pediatric Patients with Relapsed or Refractory Classical Hodgkin Lymphoma in Keynote-051: Response by 2007 Revised Response Criteria for Lymphoma and 2014 Lugano Classification
    Geoerger, B.
    Pappo, A.
    Kang, H. J.
    Macy, M. E.
    Dubois, S.
    Watt, T.
    Rossig, C.
    Vinti, L.
    Hayashi, R.
    Pathiraja, K.
    Gozman, A.
    Diede, S. J.
    Petrilli, A. S.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S206 - S207
  • [2] PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY
    Moskowitz, C.
    Zinzani, P. L.
    Fanale, M. A.
    Armand, P.
    Johnson, N.
    Ribrag, V.
    Radford, J.
    von Tresckow, B.
    Tomita, A.
    Shipp, M.
    Wang, Y.
    Ricart, A. D.
    Balakumaran, A.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 44 - 44
  • [3] MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087
    Moskowitz, C.
    Zinzani, P. L.
    Fanale, M. A.
    Armand, P.
    Johnson, N.
    Ribrag, V.
    Radford, J.
    von Tresckow, B.
    Tomita, A.
    Shipp, M. A.
    Wang, Y.
    Ricart, A. D.
    Balakumaran, A.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 319 - 319
  • [4] Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
    Moskowitz, Craig H.
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie A.
    Radford, John A.
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Gustafson, Eric
    Zhang, Yinghua
    Ricart, Alejandro Daniel
    Balakumaran, Arun
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [5] Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
    Chen, Robert W.
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie
    Ribrag, Vincent
    Radford, John A.
    Tomita, Akihiro
    Shipp, Margaret Ann
    Wang, Yang
    Ricart, Alejandro Daniel
    Balakumaran, Arun
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
    Armand, Philippe
    Zinzani, Pier Luigi
    Lee, Hun Ju
    Johnson, Nathalie A.
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Herrera, Alex F.
    Lin, Jianxin
    Kim, Eunhee
    Chakraborty, Samhita
    Marinello, Patricia
    Moskowitz, Craig H.
    BLOOD, 2023, 142 (10) : 878 - 886
  • [7] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
    Chen, Robert
    Zinzani, Pier Luigi
    Lee, Hun Ju
    Armand, Philippe
    Johnson, Nathalie A.
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Lin, Jianxin
    Kim, Eunhee
    Nahar, Akash
    Balakumaran, Arun
    Moskowitz, Craig H.
    BLOOD, 2019, 134 (14) : 1144 - 1153
  • [8] Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
    Zinzani, Pier Luigi
    Lee, Hun Ju
    Armand, Philippe
    Johnson, Nathalie
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    Von Tresckow, Bastian
    Shipp, Margaret A.
    Herrera, Alex F.
    Lin, Jianxin
    Kim, Eunhee
    Farooqui, Mohammed
    Marinello, Patricia
    Moskowitz, Craig H.
    BLOOD, 2019, 134
  • [9] Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
    Armand, Philippe
    Zinzani, Pier Luigi Luigi
    Lee, Hun Ju
    Johnson, Nathalie
    Brice, Pauline
    Radford, John
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Herrera, Alex F.
    Lin, Jianxin
    Kim, Eunhee
    Chakraborty, Samhita
    Marinello, Patricia
    Moskowitz, Craig H.
    BLOOD, 2021, 138
  • [10] Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
    von Tresckow, Bastian
    Fanale, Michelle
    Ardeshna, Kirit M.
    Chen, Robert
    Meissner, Julia
    Morschhauser, Franck
    Moskowitz, Craig
    Zinzani, Pier Luigi
    Giezek, Hilde
    Balakumaran, Arun
    Vo, Thao T.
    Raut, Monika
    Brice, Pauline
    LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2705 - 2711
1234